Pictilisib (BioDeep_00000859077)

   


代谢物信息卡片


Pictilisib

化学式: C23H27N7O3S2 (513.1616712000001)
中文名称: 2-(1H-吲唑-4-基)-6-[[4-(甲基磺酰基)-1-哌嗪基]甲基]-4-(4-吗啉基)噻吩并[3,2-D]嘧啶
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
InChI: InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)

描述信息

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor

同义名列表

2 个代谢物同义名

Pictilisib; GDC-0941



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • David M Andrews, Sharon Cartic, Sabina Cosulich, Nullin Divecha, Paul Faulder, Vikki Flemington, Oliver Kern, Jason G Kettle, Ellen MacDonald, Jennifer McKelvie, Kurt G Pike, Bryan Roberts, Rachel Rowlinson, James M Smith, Martin Stockley, Martin E Swarbrick, Iris Treinies, Michael J Waring. Identification and optimization of a novel series of selective PIP5K inhibitors. Bioorganic & medicinal chemistry. 2022 01; 54(?):116557. doi: 10.1016/j.bmc.2021.116557. [PMID: 34922306]
  • Qin Yue, S Cyrus Khojasteh, Sungjoon Cho, Shuguang Ma, Teresa Mulder, John Chen, Jodie Pang, Xiao Ding, Alan Deese, Jackson D Pellet, Nicholas Siebers, Lori Joas, Laurent Salphati, Joseph A Ware. Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Jul; 51(7):796-810. doi: 10.1080/00498254.2021.1923859. [PMID: 33938357]
  • Stefanie Deinhardt-Emmer, Laura Jäckel, Clio Häring, Sarah Böttcher, Janine J Wilden, Brigitte Glück, Regine Heller, Michaela Schmidtke, Mirijam Koch, Bettina Löffler, Stephan Ludwig, Christina Ehrhardt. Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice. Biomolecules. 2021 05; 11(6):. doi: 10.3390/biom11060808. [PMID: 34072389]
  • Magdalena Rausch, Andrea Weiss, Joanna Achkhanian, Andrei Rotari, Patrycja Nowak-Sliwinska. Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. British journal of cancer. 2020 08; 123(4):556-567. doi: 10.1038/s41416-020-0890-y. [PMID: 32439932]
  • Bingbing Zhao, Chengwu Zhao, Xiaohan Hu, Shan Xu, Zhou Lan, Yuping Guo, Zunhua Yang, Wufu Zhu, Pengwu Zheng. Design, synthesis and 3D-QSAR analysis of novel thiopyranopyrimidine derivatives as potential antitumor agents inhibiting A549 and Hela cancer cells. European journal of medicinal chemistry. 2020 Jan; 185(?):111809. doi: 10.1016/j.ejmech.2019.111809. [PMID: 31683104]
  • Xiaojing Wang, Wesley Blackaby, Vivienne Allen, Grace Ka Yan Chan, Jae H Chang, Po-Chang Chiang, Coura Diène, Jason Drummond, Steven Do, Eric Fan, Eric B Harstad, Alastair Hodges, Huiyong Hu, Wei Jia, William Kofie, Aleksandr Kolesnikov, Joseph P Lyssikatos, Justin Ly, Mizio Matteucci, John G Moffat, Veerendra Munugalavadla, Jeremy Murray, David Nash, Cameron L Noland, Geoff Del Rosario, Leanne Ross, Craig Rouse, Andrew Sharpe, Dionysos Slaga, Minghua Sun, Vickie Tsui, Heidi Wallweber, Shang-Fan Yu, Allen J Ebens. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma. Journal of medicinal chemistry. 2019 02; 62(4):2140-2153. doi: 10.1021/acs.jmedchem.8b01857. [PMID: 30715878]
  • Denise Rageot, Thomas Bohnacker, Anna Melone, Jean-Baptiste Langlois, Chiara Borsari, Petra Hillmann, Alexander M Sele, Florent Beaufils, Marketa Zvelebil, Paul Hebeisen, Wolfgang Löscher, John Burke, Doriano Fabbro, Matthias P Wymann. Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. Journal of medicinal chemistry. 2018 11; 61(22):10084-10105. doi: 10.1021/acs.jmedchem.8b01262. [PMID: 30359003]
  • Nicole Willemsen-Seegers, Joost C M Uitdehaag, Martine B W Prinsen, Judith R F de Vetter, Jos de Man, Masaaki Sawa, Yusuke Kawase, Rogier C Buijsman, Guido J R Zaman. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of molecular biology. 2017 02; 429(4):574-586. doi: 10.1016/j.jmb.2016.12.019. [PMID: 28043854]
  • Noboru Yamamoto, Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Satoru Iwasa, Yuko Tanabe, Atsushi Horiike, Noriko Yanagitani, Satoru Kitazono, Michiyasu Inatani, Jun Tanaka, Makoto Nishio. Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer. Investigational new drugs. 2017 02; 35(1):37-46. doi: 10.1007/s10637-016-0382-3. [PMID: 27565810]
  • Marco Falasca, Justin R Hamilton, Maria Selvadurai, Krithika Sundaram, Aleksandra Adamska, Philip E Thompson. Class II Phosphoinositide 3-Kinases as Novel Drug Targets. Journal of medicinal chemistry. 2017 01; 60(1):47-65. doi: 10.1021/acs.jmedchem.6b00963. [PMID: 27644332]
  • Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J Asad, Alan T Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D Baird, Lori Friedman, Mika Derynck, Bart Vanhaesebroeck, Suzanne A Eccles, Stan B Kaye, Paul Workman, Johann S de Bono, Florence I Raynaud. Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular cancer therapeutics. 2016 06; 15(6):1412-24. doi: 10.1158/1535-7163.mct-15-0815. [PMID: 27048952]
  • Wei Yang, Sarah R Hosford, Lloye M Dillon, Kevin Shee, Stephanie C Liu, Jennifer R Bean, Laurent Salphati, Jodie Pang, Xiaolin Zhang, Michelle A Nannini, Eugene Demidenko, Darcy Bates, Lionel D Lewis, Jonathan D Marotti, Alan R Eastman, Todd W Miller. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 05; 22(9):2250-60. doi: 10.1158/1078-0432.ccr-15-2276. [PMID: 26733612]
  • Oscar Lindblad, Julhash U Kazi, Lars Rönnstrand, Jianmin Sun. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner. Cellular and molecular life sciences : CMLS. 2015 Nov; 72(22):4399-407. doi: 10.1007/s00018-015-1944-9. [PMID: 26040420]
  • Ana Ortega-Molina, Elena Lopez-Guadamillas, Julie A Mattison, Sarah J Mitchell, Maribel Muñoz-Martin, Gema Iglesias, Vincent M Gutierrez, Kelli L Vaughan, Mark D Szarowicz, Ismael González-García, Miguel López, David Cebrián, Sonia Martinez, Joaquin Pastor, Rafael de Cabo, Manuel Serrano. Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys. Cell metabolism. 2015 Apr; 21(4):558-70. doi: 10.1016/j.cmet.2015.02.017. [PMID: 25817535]
  • Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A Clarke, Florence I Raynaud, Gallia Levy, Joseph A Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M Spoerke, Mark R Lackner, Yibing Yan, Lori S Friedman, Stan B Kaye, Mika K Derynck, Paul Workman, Johann S de Bono. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan; 21(1):77-86. doi: 10.1158/1078-0432.ccr-14-0947. [PMID: 25370471]
  • Laurent Salphati, Sheerin Shahidi-Latham, Cristine Quiason, Kai Barck, Merry Nishimura, Bruno Alicke, Jodie Pang, Richard A Carano, Alan G Olivero, Heidi S Phillips. Distribution of the phosphatidylinositol 3-kinase inhibitors Pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models-assessment by matrix-assisted laser desorption ionization imaging. Drug metabolism and disposition: the biological fate of chemicals. 2014 Jul; 42(7):1110-6. doi: 10.1124/dmd.114.057513. [PMID: 24754926]
  • Congfen Li, Chikara Takahashi, Liangxuan Zhang, Mahrukh Huseni, Basha Stankovich, Haider Mashhedi, Joanna Lee, Dorothy French, Jeff Eastham Anderson, Doris Kim, Kathy Howell, Matthew J Brauer, Marcin Kowanetz, Yibing Yan, Eric Humke, Allen Ebens, Garret Hampton, Mark R Lackner, Priti Hegde, Shidong Jia. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma. Journal of translational medicine. 2013 Mar; 11(?):76. doi: 10.1186/1479-5876-11-76. [PMID: 23522020]
  • Mariana Nacht, Lixin Qiao, Michael P Sheets, Thia St Martin, Matthew Labenski, Hormoz Mazdiyasni, Russell Karp, Zhendong Zhu, Prasoon Chaturvedi, Deepa Bhavsar, Deqiang Niu, William Westlin, Russell C Petter, Aravind Prasad Medikonda, Juswinder Singh. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. Journal of medicinal chemistry. 2013 Feb; 56(3):712-21. doi: 10.1021/jm3008745. [PMID: 23360348]
  • Edna F Choo, Chee M Ng, Leanne Berry, Marcia Belvin, Nicholas Lewin-Koh, Mark Merchant, Laurent Salphati. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer chemotherapy and pharmacology. 2013 Jan; 71(1):133-43. doi: 10.1007/s00280-012-1988-6. [PMID: 23053270]
  • Masato Takeuchi, Shizuka Sakiyama, Takako Usuki, Hiromichi Sakai, Fumio Sakane. Diacylglycerol kinase δ1 transiently translocates to the plasma membrane in response to high glucose. Biochimica et biophysica acta. 2012 Dec; 1823(12):2210-6. doi: 10.1016/j.bbamcr.2012.08.019. [PMID: 22974639]
  • Hidenori Nishida, Eisei Sohara, Naohiro Nomura, Motoko Chiga, Dario R Alessi, Tatemitsu Rai, Sei Sasaki, Shinichi Uchida. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension (Dallas, Tex. : 1979). 2012 Oct; 60(4):981-90. doi: 10.1161/hypertensionaha.112.201509. [PMID: 22949526]
  • Timothy P Heffron, Laurent Salphati, Bruno Alicke, Jonathan Cheong, Jennafer Dotson, Kyle Edgar, Richard Goldsmith, Stephen E Gould, Leslie B Lee, John D Lesnick, Cristina Lewis, Chudi Ndubaku, Jim Nonomiya, Alan G Olivero, Jodie Pang, Emile G Plise, Steve Sideris, Sean Trapp, Jeffrey Wallin, Lan Wang, Xiaolin Zhang. The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α. Journal of medicinal chemistry. 2012 Sep; 55(18):8007-20. doi: 10.1021/jm300867c. [PMID: 22946614]
  • Jeffrey J Wallin, Jane Guan, Wei Wei Prior, Leslie B Lee, Leanne Berry, Lisa D Belmont, Hartmut Koeppen, Marcia Belvin, Lori S Friedman, Deepak Sampath. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Jul; 18(14):3901-11. doi: 10.1158/1078-0432.ccr-11-2088. [PMID: 22586300]
  • Brian S Safina, Stewart Baker, Matt Baumgardner, Paul M Blaney, Bryan K Chan, Yung-Hsiang Chen, Matthew W Cartwright, Georgette Castanedo, Christine Chabot, Arnaud J Cheguillaume, Paul Goldsmith, David M Goldstein, Bindu Goyal, Timothy Hancox, Raj K Handa, Pravin S Iyer, Jasmit Kaur, Rama Kondru, Jane R Kenny, Sussie L Krintel, Jun Li, John Lesnick, Matthew C Lucas, Cristina Lewis, Sophie Mukadam, Jeremy Murray, Alan J Nadin, Jim Nonomiya, Fernando Padilla, Wylie S Palmer, Jodie Pang, Neil Pegg, Steve Price, Karin Reif, Laurent Salphati, Pascal A Savy, Eileen M Seward, Stephen Shuttleworth, Sukhjit Sohal, Zachary K Sweeney, Suzanne Tay, Parcharee Tivitmahaisoon, Bohdan Waszkowycz, Binqing Wei, Qin Yue, Chenghong Zhang, Daniel P Sutherlin. Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. Journal of medicinal chemistry. 2012 Jun; 55(12):5887-900. doi: 10.1021/jm3003747. [PMID: 22626259]
  • Giovanna Bergamini, Kathryn Bell, Satoko Shimamura, Thilo Werner, Andrew Cansfield, Katrin Müller, Jessica Perrin, Christina Rau, Katie Ellard, Carsten Hopf, Carola Doce, Daniel Leggate, Raffaella Mangano, Toby Mathieson, Alison O'Mahony, Ivan Plavec, Faiza Rharbaoui, Friedrich Reinhard, Mikhail M Savitski, Nigel Ramsden, Emilio Hirsch, Gerard Drewes, Oliver Rausch, Marcus Bantscheff, Gitte Neubauer. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nature chemical biology. 2012 Apr; 8(6):576-82. doi: 10.1038/nchembio.957. [PMID: 22544264]
  • X Ding, G Morrison, B Dean, C E C A Hop, L Tobler, S Percey, M Meng, S Reuschel, D A West, S Holden, J A Ware. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. Journal of pharmaceutical and biomedical analysis. 2012 Mar; 61(?):1-7. doi: 10.1016/j.jpba.2011.11.005. [PMID: 22169467]
  • Laurent Salphati, Jodie Pang, Emile G Plise, Bilin Chou, Jason S Halladay, Alan G Olivero, Patrick J Rudewicz, Qingping Tian, Susan Wong, Xiaolin Zhang. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica; the fate of foreign compounds in biological systems. 2011 Dec; 41(12):1088-99. doi: 10.3109/00498254.2011.603386. [PMID: 21838594]
  • S J Shuttleworth, F A Silva, A R L Cecil, C D Tomassi, T J Hill, F I Raynaud, P A Clarke, P Workman. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Current medicinal chemistry. 2011; 18(18):2686-714. doi: 10.2174/092986711796011229. [PMID: 21649578]
  • Todd W Miller, Brent N Rexer, Joan T Garrett, Carlos L Arteaga. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast cancer research : BCR. 2011; 13(6):224. doi: 10.1186/bcr3039. [PMID: 22114931]
  • Morag K Mansley, Stuart M Wilson. Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption. British journal of pharmacology. 2010 Oct; 161(3):571-88. doi: 10.1111/j.1476-5381.2010.00898.x. [PMID: 20880397]
  • Laurent Salphati, Leslie B Lee, Jodie Pang, Emile G Plise, Xiaolin Zhang. Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug metabolism and disposition: the biological fate of chemicals. 2010 Sep; 38(9):1422-6. doi: 10.1124/dmd.110.034256. [PMID: 20522663]
  • Laurent Salphati, Harvey Wong, Marcia Belvin, Delia Bradford, Kyle A Edgar, Wei Wei Prior, Deepak Sampath, Jeffrey J Wallin. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug metabolism and disposition: the biological fate of chemicals. 2010 Sep; 38(9):1436-42. doi: 10.1124/dmd.110.032912. [PMID: 20538720]
  • Paul Workman, Paul A Clarke, Florence I Raynaud, Rob L M van Montfort. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer research. 2010 Mar; 70(6):2146-57. doi: 10.1158/0008-5472.can-09-4355. [PMID: 20179189]